Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Iceland Genomics and Myriad form cancer gene deal:

This article was originally published in Clinica

Executive Summary

Biopharmaceutical firm Iceland Genomics has entered into cancer gene discovery collaboration with Myriad Genetics. Under the terms of the agreement, Myriad will supply genetic markers, which Reykjavik-based Iceland Genomics will use with its proprietary sample collection to help Myriad localise and identify a cancer gene. Iceland Genomics will receive research support and milestone payments and royalties on any diagnostic or therapeutic products that are developed by Myriad on the basis of the gene, said the firm. Financial details of the collaboration were not disclosed.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT067015

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel